GLAXO U.S. CHIEF EXEC-DESIGNATE ERNEST MARIO will assume the top spot at the U.S. subsidiary on July 1, succeeding Joseph Ruvane, the company announced in a June 13 release. Currently president and chief operating officer, Ernest Mario, PhD, will also have responsibility for Glaxo Canada and Glaxo Latin America. Exec VP Thomas D'Alonzo will share top operating responsibilities with Mario. Glaxo foreshadowed the management shift with the appointment of Mario to the board of Glaxo Holdings P.L.C. in March. ("The Pink Sheet" March 21, 1988 "In Brief"). Mario, 50, joined Glaxo as president in 1986 from Squibb. Formerly, he had been VP of manufacturing operations at SmithKline. "The naming of Dr. Mario to these additional posts is in keeping with our overall plan to turn over operating responsibilities in an orderly fashion," Ruvane noted in the release. Ruvane, 63, is relinquishing the chairmanship and his Glaxo Holdings seat which he has held since 1986. Ruvane joined Glaxo in 1981 as president of Glaxo Inc. He oversaw the dramatic growth of Glaxo from the 65th largest drug firm in the U.S. prior to the Zantac launch to its current position in the top five. Ruvane will become vice-chairman and remain a member of the Glaxo Inc. board of directors.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.
US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.
Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.
